8.0. Under a dissecting microscope the kidney tissue was teased with fine forceps in order to remove adherent hematopoietic tissue. Individual killifish proximal tubules were dissected and transferred to an aluminum foil-covered, teflon incubation chamber containing 1.5ml of marine teleost saline with fluroescent compound and added effectors. The chamber floor was a 4×4cm glass cover slip to which the tubules adhered lightly and through which the tissue could be viewed by means of an inverted confocal laser scanning microscope. The fluorescent compounds were dissolved in dimethylsulphoxide (DMSO) and added to the incubation medium. Preliminary experiments showed that the concentrations of DMSO used (<1%) had no significant effects on the uptake and distribution of the fluorescent labelled test compounds as measured by confocal and epifluorescence microscopy. HPTLC analysis of tubule extracts showed no degradation of NBD-octreotide, FL-methotrexate and NBDL-CS in the tissue after one hour incubations.
Fluorescence intensities were measured from stored images using the Image 1.61 software as described previously (Miller & Pritchard, 1991). From each tubule under investigation, several adjacent cellular and luminal areas (100–300 pixels each) were selected. The background fluorescence intensity was substracted and then, the average pixel intensity for each area was calculated. The values used for that tubule were the means for all selected areas.
Results Figure 1 shows a representative confocal micrograph of a killifish proximal tubule after 30min incubation in medium containing 1μM NBD-octreotide. The fluorescence intensity of the lumen is substantially higher than the cells which, in turn, is higher than the fluorescence intensity of the medium. Figure 2 shows the time course of accumulation of 1μM NBD-octreotide in tubules. Luminal and cellular fluorescence increased initially, but then reached a steady state value within 30min. At all times, luminal fluorescence exceeded cellular fluorescence and at 30–60min the lumen to cell fluorescence ratio averaged about six. In the steady state the lumen to medium ratio of NBD-octreotide ranged from 25–35. Figure 2 also shows that addition of 1mM NaCN to the medium substantially decreased luminal fluorescence, but had little effect on cellular fluorescence. After 30–60min luminal fluorescence in NaCN-treated tubules was about equal to cellular fluorescence. The control tubules exhibited the same fluorescence distribution seen previously with a variety of actively excreted fluorescent drugs and drug derivatives (Schramm et al., 1995; Miller et al., 1997; Gutmann et al., 1999; Masereeuw et al., 1996). We take this to indicate accumulation of NBD-octreotide within the cells and tubular lumens. The profound effect of NaCN on luminal NBD-octreotide accumulation indicates energy-dependent transport of the peptide from cell to lumen. The absence of effect of NaCN on cellular NBD-octreotide accumulation indicates that uptake by cells was dependent on passive mechanisms, e.g, diffusion and compartmentation. | Figure 1Confocal micrograph showing steady state distribution of NBD-octreotide fluorescence in a killifish renal proximal tubule. The bar represents 10μM. |
| Figure 2Time course of transport of NBD-octreotide in killifish proximal tubules. Tubular tissue was incubated with 1μM NBD-octreotide in teleost Ringer solution (means±s.e.mean of n=12). |
Addition of unlabelled octreotide to the medium caused a concentration dependent decrease in luminal NBD-octreotide accumulation (Figure 3). The concentration of octreotide causing a 50% reduction in luminal accumulation was between 5 and 10μM. Cellular accumulation of the labelled drug was not affected, except at the highest concentration of octreotide tested (20μM caused a 32% decrease, P<0.05). In addition, several inhibitors of transport mediated by Pgp and Mrp2 were potent inhibitors of luminal NBD-octreotide accumulation (Figure 4). These included CSA and SDZ-PSC 833 (IC50 between 5 and 10μM), verapamil (IC50 about 10μM) and LTC4 (IC50 between 0.3 and 0.5μM). In renal proximal tubule, the latter two inhibitors have been shown previously to be specific for p-glycoprotein- and Mrp2-mediated transport, respectively (Masereeuw et al., 1996; Gutmann et al., 1999). None of these compounds affected cellular NBD-octreotide accumulation (Figure 4). | Figure 3Effects of octreotide on the transport of NBD-octreotide. Tubules were incubated in medium with 1μM NBD-octreotide without or with the indicated concentration of unlabelled octreotide. Data are given as mean±s.e.mean for 10 tubules. (more ...) |
| Figure 4Effects of inhibitors of Pgp and Mrp2 on NBD-octreotide transport. Tubules were incubated in medium with 1μM NBD-octreotide without (control) or with 10μM verapamil, 5μM CSA, 5μM SDZ (more ...) |
Based on substrate and inhibitor specificity studies and immunostaining experiments with mammalian antibodies specific to Pgp and Mrp2, we have found in killifish proximal tubules that cell to lumen transport mediated by Pgp and Mrp2 can be monitored using NBDL-CS and FL-MTX, respectively (Schramm et al., 1995; Masereeuw et al., 1996, Gutmann et al., 1999). Consistent with this, Figure 5 shows that the Pgp inhibitor, verapamil, reduced cell to lumen transport of NBDL-CS, but had no effects on the transport of FL-MTX and that the Mrp2 inhibitor, LTC4, reduced cell to lumen transport of FL-MTX, but had no effects on transport of NBDL-CS. Neither verapamil nor LTC4 affected cellular accumulation of NBDL-CS or FL-MTX. | Figure 5Effects of 10μM verapamil and 0.3μM LTC4 on the transport of NBDL-CS and FL-MTX. Killifish tubules were incubated in medium containing 1μM NBDL-CS or FL-MTX and LTC4 or verapamil as additives. Data are (more ...) |
Figure 6 shows that unlabelled octreotide caused concentration-dependent reductions in the luminal accumulation of NBDL-CS and FL-MTX. For both substrates, the concentration of octreotide causing 50% reduction in luminal accumulation was about 10μM. Octreotide did not significantly affect the cellular accumulation of FL-MTX or NBD-CSA (Figure 6A,B). In contrast to the results of experiments with NBD-octreotide, NBDL-CS and FL-MTX as substrates, octreotide had no effects at all on the luminal or cellular accumulation of FL. FL is a substrate for the Na-dependent renal organic anion transport system, which is particularly sensitive to treatments that reduce cell metabolism or viability (Pritchard & Miller, 1993). | Figure 6Effects of octreotide on transport of FL-MTX (A) and NBDL-CS (B). Tubules were incubated in medium with 1μM fluorescent compound without (control) or with the indicated concentrations of octreotide. Data are given as mean±s.e.mean (more ...) |
|
Discussion It was the aim of the present work to study the mechanisms underlying the epithelial transport of the cyclic somatostatin analogue peptide octreotide. Transport of this peptide across epithelial tissues is of special interest for several reasons: First, octreotide is pharmacologically active after oral administration, however its bioavailability is normally below 1% with a perferential absorption site in the upper GI-tract (Fricker et al., 1992). One reason for differential absorption in distinct regions of the gut may be an interaction with ATP-dependent excretory systems located in the apical membrane of enterocytes as has been observed for another cyclic peptide, cyclosporin A (Augustjins et al., 1993; Fricker et al. 1996). Second, octreotide has a rather short plasma half life and a relatively high hepatic and renal elimination (Chanson et al., 1993; Harris, 1994; Fricker et al., 1994). There is evidence that the peptide is secreted by one or more of the hepatic excretory carrier systems in the bile canalicular plasma membrane (Yamada et al., 1996; 1998). Third, small somatostatin analogs permeate the blood–brain barrier only to a neglegible extent (Jaehde et al., 1994; Banks et al., 1990), most probably due to an interaction with excretory proteins (Kitazawa et al., 1998). Finally, 111In-DTPA-conjugated octreotide analogues showed accumulation in the kidney with about 60% injected radioactivity being excreted in the urine by 24h post injection. Thereby, over 85% of the radioactivity in the urine represented intact peptide (Akizawa et al., 1998). The fate of such radiolabelled octreotide derivatives in the kidney is of interest, because they are used for radiodiagnostic purposes in oncology and exhibit high renal accumulation (Bernard et al., 1997; de Jong et al., 1996; Akizawa et al., 1998; Breman et al., 1998). In the present study, the transport of an NBD derivative of octreotide from bath to urinary space was studied in killifish renal proximal tubules, a well-established comparative model for the investigation of carrier-mediated excretory drug transport. NBD octreotide was accumulated by the cells and excreted into the lumen by a concentrative process. Previous studies from our laboratories have demonstrated that, in addition to the classical renal organic anion and organic cation transport systems, these tubules possess both Pgp and Mrp2 (Schramm et al., 1995; Miller, 1995; Masereuw et al., 1996, Miller et al., 1997; Gutmann et al., 1999; Fricker et al., 1999). Moreover, we have shown, that Pgp, the mdr1 gene product, is able to transport lipophilic cyclic oligopeptides like cyclosporin A in killifish proximal tubules (Schramm et al., 1995) and that Mrp2, the multidrug resistance associated protein, recognizes substrates with peptide like structures, like HIV-protease inhibitors (Gutmann et al., 1999). The transport of NBD-octreotide into the luminal space of proximal tubules had all the hallmarks of an active, carrier-mediated process. First, luminal accumulation exceeded cellular accumulation by a factor of 4–6; second, luminal accumulation was reduced to cellular levels when metabolism was inhibited by NaCN; third, luminal accumulation was reduced in a concentration-dependent manner by octreotide itself and by compounds that competitively inhibit transport mediated by Pgp and Mrp2, i.e. CSA, PSC-833, verapamil and LTC4. In killifish tubules, inhibition by the latter two compounds has been taken as evidence for the involvement of Pgp and Mrp2, respectively (Gutmann et al., 1999; Fricker et al., 1999). In contrast, neither NaCN nor any of the other inhibitors of transport had any consistent effects on cellular accumulation of NBD-octreotide. This suggests that cellular accumulation of this fluorescent derivative is passive and non-mediated. As with other lipophillic drugs, e.g., CSA and rapamycin (Schramm et al., 1995; Miller, et al., 1997), the increase in fluorescence in cells over that in the medium probably reflects accumulation of the drug in cellular membranes and other compartments. The lack of effect of inhibitors on steady state cellular fluorescence indicates that drug efflux to the lumen is not a major determinant of cell levels, as has been found previously for several secreted compounds (Schramm et al., 1995; Miller et al., 1997; Gutmann et al., 1999). Consistent with octreotide interacting with both Pgp and Mrp2, we found that unlabelled octreotide was a potent inhibitor of cell to lumen transport of NBDL-CS and FL-MTX. This inhibition was not due to toxicity or non-specific effects, since octeotide had no effects on the transport of the small organic anion, FL. This compound is handled by the classical renal organic anion transport system, which is particularly sensitive to disrupted metabolism or ion gradients (Pritchard & Miller, 1993). Taken together, these data provide evidence that octreotide is a substrate for both Pgp and mrp2. Knowledge of the excretory mechanisms underlying epithelial transport of octreotide may be of relevance to influence the pharmacokinetic properties of this therapeutic peptide. In summary, these date demonstrate that octreotide inhibits drug secretion mediated by p-glycoprotein and Mrp2 and may therefore contribute to clinical relevant drug–drug interactions. The experiments with the fluorescent octreotide derivative suggest that efflux of octreotide in renal proximal tubules may be mediated by p-glycoprotein and Mrp2. |
References - ABE, T.; MORI, T.; HORI, S.; KOIKE, K.; KUWANO, M. Multidrug resistance protein (MRP). Nippon Rinsho. 1997;55:1077–1082. [PubMed]
- AKIZAWA, H.; ARANO, Y.; UEZONO, T.; ONO, M.; FUJIOKA, Y.; UEHARA, T.; YOKOYAMA, A.; AKAJI, K.; KISO, Y.; KOIZUMI, M.N.; SAJI, H. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo. Bioconjug. Chem. 1998;9:662–670. [PubMed]
- AUGUSTIJNS, P.F.; BRADSHAW, T.P.; GAN, L.S.; HENDREN, R.W.; THAKKER, D.R. Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 1993;197:360–365. [PubMed]
- BANKS, W.A.; SCHALLY, A.V.; BARRERA, C.M.; FASOLD, M.B.; DURHAM, D.A.; CSERNUS, V.J.; GROOT, K.; KASTIN, A.J. Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. Proc. Natl. Acad. Sci. U.S.A. 1990;87:6762–6766. [PubMed]
- BERNARD, B.F.; KRENNING, E.P.; BREEMAN, W.A.; ROLLEMAN, E.J.; BAKKER, W.H.; VISSER, T.J.; MACKE, H.; DE JONG, M. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J. Nucl. Med. 1997;38:1929–1933. [PubMed]
- CHANSON, P.; TIMSIT, J.; HARRIS, A.G. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin. Pharmacokin. 1993;25:375–391.
- DE JONG, M.; ROLLEMAN, E.J.; BERNARD, B.F.; VISSER, T.J.; BAKKER, W.H.; BREEMAN, W.A.; KRENNING, E.P. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J. Nucl. Med. 1996;37:1388–1392. [PubMed]
- DREWE, J.; FRICKER, G.; VONDERSCHER, J.; BEGLINGER, C. Enteral absorption of octreotide. Absorption enhancement by polyoxyethylene-24-cholesterol ether. Brit. J. Pharmacol. 1993;108:298–303. [PubMed]
- FORSTER, R.P.; TAGGART, J.V. Use of isolated renal tubules in the estimation of metabolic processes associated with active cellular transport. J. Cell. Comp. Physiol. 1950;36:251–270.
- FRICKER, G.; BRUNS, C.; MUNZER, J.; BRINER, U.; ALBERT, R.; KISSEL, T.; VONDERSCHER, J. Intestinal absorption of the octapeptide SMS 201-995 visualized by fluorescence derivatization. Gastroenterology. 1991;100:1544–1552. [PubMed]
- FRICKER, G.; DREWE, J.; HUWYLER, J.; GUTMANN, H.; BEGLINGER, C. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A. In vitro-in vivo correlation. Brit. J. Pharmacol. 1996;118:1841–1847. [PubMed]
- FRICKER, G.; DREWE, J.; VONDERSCHER, J.; BEGLINGER, C. Enteral absorption of octreotide. Brit. J. Pharmacol. 1992;105:783–786. [PubMed]
- FRICKER, G.; DUBOST, V.; SCHWAB, D.; BRUNS, C.; THIELE, C. Heterogeneity in hepatic transport of somatostatin analogue peptides. Hepatology. 1994;20:191–200. [PubMed]
- FRICKER, G.; GUTMANN, H.; DROULLE, A.; DREWE, J.; MILLER, D.S. Epithelial transport of anthelmintic Ivermectin in a novel model of isolated proximal kidney tubules. Pharm. Res. 1999;16:1570–1575. [PubMed]
- FUESSL, H.S.; DOMIN, J.; BLOOM, S.R. Oral absorption of the somatostatin analogue SMS 201–995: theoretical and practical implications. Clin. Sci. 1987;72:255–257. [PubMed]
- GOTTESMAN, M.M.; PASTAN, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993;62:385–427. [PubMed]
- GUTMANN, H.; MILLER, D.; DREWE, J.; TÖRÖK, M.; FRICKER, G. Interaction of HIV-protease inhibitors with ATP-dependent drug export proteins. Mol. Pharmacol. 1999;56:383–389. [PubMed]
- HARRIS, A.G. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut. 1994;35:S1–S4.
- JAEHDE, U.; MASEREEUW, R.; DE BOER, A.G.; FRICKER, G.; NAGELKERKE, J.F.; VONDERSCHER, J.; BREIMER, D.D. Quantification and visualization of the transport of octreotide, a somatostatin analogue, across monolayers of cerebrovascular endothelial cells. Pharm. Res. 1994;11:442–448. [PubMed]
- KITAZAWA, T.; TERASAKI, T.; SUZUKI, H.; KAKEE, A.; SUGIYAMA, Y. Efflux of taurocholic acid across the blood-brainbarrier: interaction with cyclic peptides. J. Pharmacol. Exp. Ther. 1998;286:890–895. [PubMed]
- KOEHLER, E.; DUBEROW-DREWE, M.; DREWE, J.; LOUBATIERES-MARIANI, M.M.; MAZER, N.; GYR, K.; BEGLINGER, C. Absorption of an aqueous solution of a new synthetic somatostatin analogue administered to man by gavage. Eur. J. Clin. Pharmacol. 1987;33:167–171. [PubMed]
- KUSUHARA, H.; SUZUKI, H.; SUGIYAMA, Y. The role of p-glycoprotein and a canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J. Pharm. Sci. 1998;87:1025–1040. [PubMed]
- MASEREEUW, R.; RUSSEL, F.G.; MILLER, D.S. Multiple pathways of organic anion secretion in renal proximal tubule revealed by confocal microscopy. Am. J. Physiol. 1996;271:F1173–F1182. [PubMed]
- MILLER, D.S. Aquatic models for the study of renal transport function and pollutant toxicity. Environ Health Perspect. 1987;71:59–68. [PubMed]
- MILLER, D.S. Daunomycin secretion by killfish renal proximal tubules. Am. J. Physiol. 1995;269:R370–R379. [PubMed]
- MILLER, D.S.; PRITCHARD, J.B. Indirect coupling of organic anion secretion to sodium in teleost (Paralichthys lethostigma) renal tubules. Am. J. Physiol. 1991;261:R1470–R1477. [PubMed]
- MILLER, D.S.; PRITCHARD, J.B. Dual pathways for organic anion secretion in renal proximal tubule. J. Exp. Zool. 1997;279:462–470. [PubMed]
- MILLER, D.S.; FRICKER, G.; DREWE, J. P-glycoprotein-mediated transport of a fluorescent rapamycin derivative in renal proximal tubule. J. Pharmacol. Exp. Ther. 1997;82:440–444.
- MILLER, D.S.; LETCHER, S.; BARNES, D.M. Fluorescence imaging study of organic anion transport from renal proximal tubule cell to lumen. Am. J. Physiol. 1996;271:F508–F520. [PubMed]
- OUDE ELFERINK, R.P.J.; MEIJER, D.K.F.; KUIPERS, F.; JANSEN, P.L.M.; GROOTHUIS, G.M.M. Hepatobiliary secretion of organic compounds–molecular mechanisms of membrane transport. BBA-Rev. Biomembr. 1995;1241:215–268.
- PRITCHARD, J.B.; MILLER, D.S. Comparative insights into the mechanisms of renal organic anion and cation secretion. Am. J. Physiol. 1991;261:R1329–R1340. [PubMed]
- PRITCHARD, J.B.; MILLER, D.S. Mechanisms mediating renal secretion of organic anions and cations. Physiol. Rev. 1993;73:765–796. [PubMed]
- PRITCHARD, J.B.; MILLER, D.S. Renal secretion of organic anions and cations. Kidney Internatl. 1996;49:1649–1654.
- SCHRAMM, U.; FRICKER, G.; WENGER, R.; MILLER, D.S. p-glycoprotein mediated transport of a fluorescent cyclosporin analogue in teleost proximal tubules. Am. J. Physiol. 1995;268:F46–F52. [PubMed]
- SEELIG, A. p-Glycoprotein –how does it recognize its substrates. Eur. J. Biochem. 1998;251:252–261. [PubMed]
- YAMADA, T.; KATO, Y.; KUSUHARA, H.; LEMAIRE, M.; SUGIYAMA, Y. Characterization of the transport of a cationic octapeptide, octreotide, in rat bile canalicular membrane: possible involvement of P-glycoprotein. Biol. Pharmaceut. Bull. 1998;21:874–878.
- YAMADA, T.; NIINUMA, K.; LEMAIRE, M.; TERASAKI, T.; SUGIYAMA, Y. Mechanism of the tissue distribution and biliary excretion of the cyclic peptide octreotide. J. Pharmacol. Exp. Ther. 1996;279:1357–1364. [PubMed]
|